Starling Oncology, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Starling Oncology, Inc. (DFPH) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $10.11 million for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-05-24.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2021-08-16
- Starling Oncology, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2020-03-31 was $10.11M.
- Starling Oncology, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2020 was $10.11M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month as first filed | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed |
|---|---|---|---|---|
| 2020-12-31 | $10.11M 10-K/A · filed 2021-05-24 | $10.43M 10-K · filed 2021-03-30 | ||
| 2020-03-31 | $10.11M 10-Q · filed 2021-08-16 | $10.43M 10-Q · filed 2020-05-08 |